Brain-derived neurotrophic factor and neurocognitive profiles in the psychosis spectrum: Findings in bipolar disorder and schizophrenia

Bipolar Disorder: Symptoms, Management and Risk Factors

Volumn , Issue , 2013, Pages 67-96

  Ahmed, Anthony O ^a   Fridberg, Daniel J ^a   Hanna, Mona ^a   Buckley, Peter F ^a  

^a MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84892084949     PISSN: None     EISSN: None     Source Type: Book    
DOI: None     Document Type: Chapter

References (169)

1. Singh I, Rose N. Biomarkers in psychiatry. Nature. 2009 Jul 8;460(7252):202-7.
2. Lakhan SE, Vieira K, Hamlat E. Biomarkers in psychiatry: drawbacks and potential for misuse. International Archives of Medicine. 2010 Jan 12;3(1):1.
3. Lakhan SE, Kramer A. Schizophrenia genomics and proteomics: are we any closer to biomarker discovery? Behavioral and Brain Functions. 2009 Jan 7;5(1):2.
4. Buckley PF, Mahadik S, Pillai A, Terry A Jr. Neurotrophins and schizophrenia. Schizophr. Res. 2007 Aug;94(1-3):1-11.
5. Post RM. Role of BDNF in bipolar and unipolar disorder: clinical and theoretical implications. J Psychiatr Res. 2007 Dec;41(12):979-90.
6. Walss-Bass C, Escamilla MA, Raventos H, Montero AP, Armas R, Dassori A, et al. Evidence of genetic overlap of schizophrenia and bipolar disorder: linkage disequilibrium analysis of chromosome 18 in the Costa Rican population. Am. J. Med. Genet. BNeuropsychiatr. Genet. 2005 Nov 5;139B(1):54-60.
7. Akabaliev V, Sivkov S, Mantarkov M, Ahmed-Popova F. Minor physical anomalies in patients with bipolar I disorder and normal controls. Journal of Affective Disorders. 2011 Dec;135(1-3):193-200.
8. Fatemi SH, Folsom TD. The Neurodevelopmental Hypothesis of Schizophrenia, Revisited. Schizophr. Bull. 2009 May 3;35(3):528-548.
9. Murray RM, Sham P, Van Os J, Zanelli J, Cannon M, McDonald C. A developmental model for similarities and dissimilarities between schizophrenia and bipolar disorder. Schizophr. Res. 2004 Dec 1;71(2-3):405-16.
10. Cannon TD, Van Erp TGM, Bearden CE, Loewy R, Thompson P, Toga AW, et al. Early and late neurodevelopmental influences in the prodrome to schizophrenia: contributions of genes, environment, and their interactions. Schizophr Bull. 2003;29(4-653):69-.
11. Cannon M, Murray RM. Neonatal origins of schizophrenia. Arch. Dis. Child. 1998 Jan;78(1):1-3.
12. Meehl PE. Schizotaxia revisited. Arch. Gen. Psychiatry. 1989 Oct;46(10):935-44.
13. Bitter SM, Mills NP, Adler CM, Strakowski SM, DelBello MP. Progression of amygdala volumetric abnormalities in adolescents after their first manic episode. J Am Acad Child Adolesc Psychiatry. 2011 Oct;50(10):1017-26.
14. Kapczinski F, Frey BN, Kauer-Sant'Anna M, Grassi-Oliveira R. Brain-derived neurotrophic factor and neuroplasticity in bipolar disorder. Expert Rev Neurother. 2008 Jul;8(7):1101-13.
15. Krebs MO, Guillin O, Bourdell MC, Schwartz JC, Olie JP, Poirier MF, et al. Brain derived neurotrophic factor (BDNF) gene variants association with age at onset and therapeutic response in schizophrenia. Mol. Psychiatry. 2000 Sep;5(5):558-62.
16. Jones KR, Farinas I, Backus C, Reichardt LF. Targeted disruption of the BDNF gene perturbs brain and sensory neuron development but not motor neuron development. Cell. 1994 Mar 25;76(6):989-99.
17. Mayeur S, Silhol M, Moitrot E, Barbaux S, Breton C, Gabory A, et al. Placental BDNF/TrkB Signaling System is Modulated by Fetal Growth Disturbances in Rat and Human. Placenta. 2010 Sep;31(9):785-91.
18. De Sousa RT, Van de Bilt MT, Diniz BS, Ladeira RB, Portela LV, Souza DO, et al. Lithium increases plasma brain-derived neurotrophic factor in acute bipolar mania: a preliminary 4-week study. Neurosci. Lett. 2011 Apr 20;494(1):54-6.
19. Pillai A, Buckley PF. Reliable biomarkers and predictors of schizophrenia and its treatment. Psychiatr. Clin. North Am. 2012 Sep;35(3):645-59.
20. Grande I, Kapczinski F, Stertz L, Colpo GD, Kunz M, Cereser KM, et al. Peripheral brain-derived neurotrophic factor changes along treatment with extended release quetiapine during acute mood episodes: an open-label trial in drug-free patients with bipolar disorder.. J Psychiatr Res. 2012 Nov;46(11):1511-4.
21. Huang EJ, Reichardt LF. NEUROTROPHINS: Roles in Neuronal Development and Function. Annual Review of Neuroscience. 2001;24(1-677):736-.
22. Sofroniew MV, Howe CL, Mobley WC. Nerve growth factor signaling, neuroprotection, and neural repair. Annu. Rev. Neurosci. 2001;24:1217-81.
23. Dodd S, Maes M, Anderson G, Dean OM, Moylan S, Berk M. Putative neuroprotective agents in neuropsychiatry disorders. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2013 Apr 5;42:135-45.
24. Arévalo JC, Wu SH. Neurotrophin signaling: many exciting surprises! Cell. Mol. Life Sci. 2006 Jul;63(13):1523-37.
25. Karatsoreos IN, McEwen BS. Psychobiological allostasis: resistance, resilience and vulnerability. Trends Cogn. Sci. (Regul. Ed.). 2011 Dec;15(12):576-84.
26. Skaper SD. The neurotrophin family of neurotrophic factors: an overview. Methods Mol. Biol. 2012;846:1-12.
27. Skaper SD. The biology of neurotrophins, signalling pathways, and functional peptide mimetics of neurotrophins and their receptors. CNS Neurol Disord Drug Targets. 2008 Feb;7(1):46-62.
28. Green MJ, Matheson SL, Shepherd A, Weickert CS, Carr VJ. Brain-derived neurotrophic factor levels in schizophrenia: a systematic review with meta-analysis. Mol. Psychiatry. 2011 Sep;16(9):960-72.
29. Green EK, Raybould R, Macgregor S, Hyde S, Young AH, O'Donovan MC, et al. Genetic variation of brain-derived neurotrophic factor (BDNF) in bipolar disorder: case-control study of over 3000 individuals from the UK.. Br J Psychiatry. 2006 Jan;188:21-5.
30. Teng KK, Felice S, Kim T, Hempstead BL. Understanding Proneurotrophin Actions: Recent Advances and Challenges. DevNeurobiol. 2010 Apr;70(5):350-9.
31. Huang EJ, Reichardt LF. Trk receptors: roles in neuronal signal transduction. Annu. Rev. Biochem. 2003;72:609-42.
32. Lu B, Pang PT, Woo NH. The yin and yang of neurotrophin action. Nat. Rev. Neurosci. 2005 Aug;6(8):603-14.
33. Nykjaer A, Lee R, Teng KK, Jansen P, Madsen P, Nielsen MS, et al. Sortilin is essential for proNGF-induced neuronal cell death.. Nature. 2004 Feb 26;427(6977):843-8.
34. Segal RA. Selectivity in neurotrophin signaling: theme and variations. Annu. Rev. Neurosci. 2003;26:299-330.
35. Jeanneteau F, Deinhardt K, Miyoshi G, Bennett AM, Chao MV. The MAP kinase phosphatase MKP-1 regulates BDNF-induced axon branching. Nat. Neurosci. 2010 Nov;13(11):1373-9.
36. Mullen LM, Pak KK, Chavez E, Kondo K, Brand Y, Ryan AF. Ras/p38 and P13K/Akt but not Mek/Erk signaling mediate BDNF-induced neurite formation on neonatal cochlear spiral ganglion explants. Brain Res. 2012 Jan 9;1430:25-34.
37. Mast TG, Fadool DA. Mature and precursor brain-derived neurotrophic factor have individual roles in the mouse olfactory bulb. PLoS ONE. 2012;7(2-e31978):.
38. Ichim G, Tauszig-Delamasure S, Mehlen P. Neurotrophins and cell death. Experimental Cell Research. 2012 Jul 1;318(11):1221-8.
39. Chowdhury I, Tharakan B, Bhat GK. Caspases-an update. Comp. Biochem. Physiol. B, Biochem. Mol. Biol. 2008 Sep;151(1):10-27.
40. Coleman M. Molecular signaling how do axons die? Adv. Genet. 2011;73:185-217.
41. Lamkanfi M, Festjens N, Declercq W, Vanden Berghe T, Vandenabeele P. Caspases in cell survival, proliferation and differentiation. Cell Death Differ. 2007 Jan;14(1):44-55.
42. Bode AM, Dong Z. The functional contrariety of JNK. Mol. Carcinog. 2007 Aug;46(8):591-8.
43. Sun Y, Lim Y, Li F, Liu S, Lu J-J, Haberberger R, et al. ProBDNF Collapses Neurite Outgrowth of Primary Neurons by Activating RhoA.. PLoS ONE. 2012 Apr 27;7(4):e35883.
44. Matsumoto T, Rauskolb S, Polack M, Klose J, Kolbeck R, Korte M, et al. Biosynthesis and processing of endogenous BDNF: CNS neurons store and secrete BDNF, not pro-BDNF.. Nat. Neurosci. 2008 Feb;11(2):131-3.
45. Greenberg ME, Xu B, Lu B, Hempstead BL. New Insights in the Biology of BDNF Synthesis and Release: Implications in CNS Function. J. Neurosci. 2009 Oct 14;29(41):12764-7.
46. Yang J, Siao C-J, Nagappan G, Marinic T, Jing D, McGrath K, et al. Neuronal release of proBDNF.. Nat. Neurosci. 2009 Feb;12(2):113-5.
47. Barker PA. Whither proBDNF? Nature Neuroscience. 2009;12(2): 105-6.
48. Lu Y, Christian K, Lu B. BDNF: a key regulator for protein synthesis-dependent LTP and long-term memory? Neurobiol Learn Mem. 2008 Mar;89(3):312-23.
49. Huang Y, Morozov A. Hippocampal Deletion of BDNF Gene Attenuates Gamma Oscillations in Area CA1 by Up-Regulating 5-HT3 Receptor. PLoS ONE. 2011 Jan 26;6(1):e16480.
50. Korte M, Carroll P, Wolf E, Brem G, Thoenen H, Bonhoeffer T. Hippocampal long-term potentiation is impaired in mice lacking brain-derived neurotrophic factor. Proc. Natl. Acad. Sci. U.S.A. 1995 Sep 12;92(19):8856-60.
51. Heldt SA, Stanek L, Chhatwal JP, Ressler KJ. Hippocampus-specific deletion of BDNF in adult mice impairs spatial memory and extinction of aversive memories. Mol. Psychiatry. 2007 Jul;12(7):656-70.
52. Fiore M, Korf J, Antonelli A, Talamini L, Aloe L. Long-lasting effects of prenatal MAM treatment on water maze performance in rats: associations with altered brain development and neurotrophin levels. Neurotoxicol Teratol. 2002 Apr;24(2):179-91.
53. Castrén E, Da Penha Berzaghi M, Lindholm D, Thoenen H. Differential effects of MK-801 on brain-derived neurotrophic factor mRNA levels in different regions of the rat brain. Exp. Neurol. 1993 Aug;122(2):244-52
54. Angelucci F, Mathé AA, Aloe L. Brain-derived neurotrophic factor and tyrosine kinase receptor TrkB in rat brain are significantly altered after haloperidol and risperidone administration. J. Neurosci. Res. 2000 Jun 15;60(6):783-94.
55. Jones NC, Lee HE, Yang M, Rees SM, Morris MJ, O'Brien TJ, et al. Repeatedly stressed rats have enhanced vulnerability to amygdala kindling epileptogenesis.. Psychoneuroendocrinology. 2013 Feb;38(2):263-70.
56. Friedman WJ. Proneurotrophins, Seizures, and Neuronal Apoptosis. Neuroscientist. 2010 Jun 1;16(3):244-52.
57. Matveeva EA, Vanaman TC, Whiteheart SW, Slevin JT. Asymmetric Accumulation of Hippocampal 7S SNARE Complexes Occurs Regardless of Kindling Paradigm. Epilepsy Res. 2007 Mar;73(3):266-74.
58. Houlihan LM, Harris SE, Luciano M, Gow AJ, Starr JM, Visscher PM, et al. Replication study of candidate genes for cognitive abilities: the Lothian Birth Cohort 1936.. Genes Brain Behav. 2009 Mar;8(2):238-47.
59. Zheng F, Zhou X, Luo Y, Xiao H, Wayman G, Wang H. Regulation of Brain-Derived Neurotrophic Factor Exon IV Transcription through Calcium Responsive Elements in Cortical Neurons. PLoS ONE. 2011 Dec 9;6(12):e28441.
60. Liu Q-R, Walther D, Drgon T, Polesskaya O, Lesnick TG, Strain KJ, et al. Human brain derived neurotrophic factor (BDNF) genes, splicing patterns, and assessments of associations with substance abuse and Parkinson's Disease.. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005 Apr 5;134B(1):93-103.
61. Chen Z-Y, Patel PD, Sant G, Meng C-X, Teng KK, Hempstead BL, et al. Variant brain-derived neurotrophic factor (BDNF) (Met66) alters the intracellular trafficking and activity-dependent secretion of wild-type BDNF in neurosecretory cells and cortical neurons.. J. Neurosci. 2004 May 5;24(18):4401-11.
62. Egan MF, Kojima M, Callicott JH, Goldberg TE, Kolachana BS, Bertolino A, et al. The BDNF val66met polymorphism affects activity-dependent secretion of BDNF and human memory and hippocampal function.. Cell. 2003 Jan 24;112(2):257-69.
63. Hashimoto R, Moriguchi Y, Yamashita F, Mori T, Nemoto K, Okada T, et al. Dosedependent effect of the Val66Met polymorphism of the brain-derived neurotrophic factor gene on memory-related hippocampal activity.. Neurosci. Res. 2008 Aug;61(4):360-7.
64. Sklar P, Gabriel SB, McInnis MG, Bennett P, Lim Y-M, Tsan G, et al. Family-based association study of 76 candidate genes in bipolar disorder: BDNF is a potential risk locus. Brain-derived neutrophic factor.. Mol. Psychiatry. 2002;7(6-579):93-.
65. Neves-Pereira M, Mundo E, Muglia P, King N, Macciardi F, Kennedy JL. The Brain-Derived Neurotrophic Factor Gene Confers Susceptibility to Bipolar Disorder: Evidence from a Family-Based Association Study. Am J Hum Genet. 2002 Sep;71(3):651-5.
66. Lohoff FW, Sander T, Ferraro TN, Dahl JP, Gallinat J, Berrettini WH. Confirmation of association between the Val66Met polymorphism in the brain-derived neurotrophic factor (BDNF) gene and bipolar I disorder. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2005 Nov 5;139B(1):51-3.
67. Müller DJ, Luca VD, Sicard T, King N, Strauss J, Kennedy JL. Brain-derived neurotrophic factor (BDNF) gene and rapid-cycling bipolar disorder Family-based association study. BJP. 2006 Oct 1;189(4):317-23.
68. Strauss J, Barr CL, George CJ, Devlin B, Vetró A, Kiss E, et al. Brain-derived neurotrophic factor variants are associated with childhood-onset mood disorder: confirmation in a Hungarian sample.. Mol. Psychiatry. 2005 Sep;10(9):861-7.
69. Geller B, Badner JA, Tillman R, Christian SL, Bolhofner K, Cook EH Jr. Linkage disequilibrium of the brain-derived neurotrophic factor Val66Met polymorphism in children with a prepubertal and early adolescent bipolar disorder phenotype.. Am J Psychiatry. 2004 Sep;161(9):1698-700.
70. Hong C-J, Huo S-J, Yen F-C, Tung C-L, Pan G-M, Tsai S-J. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior.. Neuropsychobiology. 2003;48(4-186):9-.
71. Nakata K, Ujike H, Sakai A, Uchida N, Nomura A, Imamura T, et al. Association study of the brain-derived neurotrophic factor (BDNF) gene with bipolar disorder.. Neurosci. Lett. 2003 Jan 30;337(1):17-20.
72. Kunugi H, Iijima Y, Tatsumi M, Yoshida M, Hashimoto R, Kato T, et al. No association between the Val66Met polymorphism of the brain-derived neurotrophic factor gene and bipolar disorder in a Japanese population: a multicenter study.. Biol. Psychiatry. 2004 Sep 1;56(5):376-8.
73. Skibinska M, Hauser J, Czerski PM, Leszczynska-Rodziewicz A, Kosmowska M, Kapelski P, et al. Association analysis of brain-derived neurotrophic factor (BDNF) gene Val66Met polymorphism in schizophrenia and bipolar affective disorder.. World J. Biol. Psychiatry. 2004 Oct;5(4):215-20.
74. Neves-Pereira M, Cheung JK, Pasdar A, Zhang F, Breen G, Yates P, et al. BDNF gene is a risk factor for schizophrenia in a Scottish population.. Mol. Psychiatry. 2005 Feb;10(2):208-12.
75. Kanazawa T, Glatt SJ, Kia-Keating B, Yoneda H, Tsuang MT. Meta-analysis reveals no association of the Val66Met polymorphism of brain-derived neurotrophic factor with either schizophrenia or bipolar disorder. Psychiatr. Genet. 2007 Jun;17(3): 165-70.
76. Rosa A, Cuesta MJ, Fatjó-Vilas M, Peralta V, Zarzuela A, Fananás L. The Val66Met polymorphism of the brain-derived neurotrophic factor gene is associated with risk for psychosis: evidence from a family-based association study. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2006 Mar 5;141B(2):135-8.
77. Chang H-A, Lu R-B, Shy M-J, Chang C-C, Lee M-S, Huang S-Y. Brain-derived neurotrophic factor Val66Met polymorphism: association with psychopathological symptoms of schizophrenia?. J Neuropsychiatry Clin Neurosci. 2009;21(1-30):7-.
78. Nanko S, Kunugi H, Hirasawa H, Kato N, Nabika T, Kobayashi S. Brain-derived neurotrophic factor gene and schizophrenia: polymorphism screening and association analysis. Schizophr. Res. 2003 Aug 1;62(3):281-3.
79. Naoe Y, Shinkai T, Hori H, Fukunaka Y, Utsunomiya K, Sakata S, et al. No association between the brain-derived neurotrophic factor (BDNF) Val66Met polymorphism and schizophrenia in Asian populations: Evidence from a case-control study and metaanalysis.. Neurosci. Lett. 2007 Mar 26;415(2):108-12.
80. Xu M-Q, St Clair D, Ott J, Feng G-Y, He L. Brain-derived neurotrophic factor gene C-270T and Val66Met functional polymorphisms and risk of schizophrenia: A moderate-scale population-based study and meta-analysis. Schizophrenia Research. 2007 Mar;1(3-6):13-.
81. Rybakowski JK. BDNF gene: functional Val66Met polymorphism in mood disorders and schizophrenia. Pharmacogenomics. 2008 Nov;9(11):1589-93.
82. Wang Z, Li Z, Chen J, Huang J, Yuan C, Hong W, et al. Association of BDNF gene polymorphism with bipolar disorders in Han Chinese population.. Genes Brain Behav. 2012 Jul;11(5):524-8.
83. De Luca V, Strauss J, Semeralul M, Huang S, Li PP, Warsh JJ, et al. Analysis of BDNF Val66Met allele-specific mRNA levels in bipolar disorder.. Neurosci. Lett. 2008 Aug 22;441(2):229-32.
84. Hajek T, Kopecek M, Höschl C. Reduced hippocampal volumes in healthy carriers of brain-derived neurotrophic factor Val66Met polymorphism: meta-analysis. World J. Biol. Psychiatry. 2012 Mar;13(3):178-87.
85. Kauppi K, Nilsson L-G, Adolfsson R, Lundquist A, Eriksson E, Nyberg L. Decreased medial temporal lobe activation in BDNF (66)Met allele carriers during memory encoding. Neuropsychologia. 2012 Dec 2;
86. Molendijk ML, Bus BAA, Spinhoven P, Kaimatzoglou A, Oude Voshaar RC, Penninx BWJH, et al. A systematic review and meta-analysis on the association between BDNF val(66)met and hippocampal volume--a genuine effect or a winners curse?. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2012 Sep;159B(6):731-40.
87. Carballedo A, Morris D, Zill P, Fahey C, Reinhold E, Meisenzahl E, et al. Brain-derived neurotrophic factor Val66Met polymorphism and early life adversity affect hippocampal volume.. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2013 Jan 22;
88. Molendijk ML, Van Tol M-J, Penninx BWJH, Van der Wee NJA, Aleman A, Veltman DJ, et al. BDNF val66met affects hippocampal volume and emotion-related hippocampal memory activity.. Transl Psychiatry. 2012;2:e74.
89. Tost H, Alam T, Geramita M, Rebsch C, Kolachana B, Dickinson D, et al. Effects of the BDNF val(66)met polymorphism on white matter microstructure in healthy adults.. Neuropsychopharmacology. 2013 Feb;38(3):525-32.
90. Kim B, Kim CY, Hong JP, Kim SY, Lee C, Joo YH. Brain-derived neurotrophic factor Val/Met polymorphism and bipolar disorder. Association of the Met allele with suicidal behavior of bipolar patients. Neuropsychobiology. 2008;58(2-97):103-.
91. Numata S, Ueno S-I, Iga J-I, Yamauchi K, Hongwei S, Ohta K, et al. Brain-derived neurotrophic factor (BDNF) Val66Met polymorphism in schizophrenia is associated with age at onset and symptoms.. Neurosci. Lett. 2006 Jun 19;401(1-2): 1-5.
92. Burghardt K j., Pop-Busui R, Bly M j., Grove T b., Taylor S f., Ellingrod V l. The Influence of the Brain-Derived Neurotropic Factor Val66Met-Genotype and HMG-CoA Reductase Inhibitors on Insulin Resistance in the Schizophrenia and Bipolar Populations.. Clinical and Translational Science. 2012;5(6-486):90-.
93. Mirakhur A, Moorhead TWJ, Stanfield AC, McKirdy J, Sussmann JED, Hall J, et al. Changes in gyrification over 4 years in bipolar disorder and their association with the brain-derived neurotrophic factor valine(66) methionine variant.. Biol. Psychiatry. 2009 Aug 1;66(3):293-7.
94. Matsuo K, Walss-Bass C, Nery FG, Nicoletti MA, Hatch JP, Frey BN, et al. Neuronal correlates of brain-derived neurotrophic factor Val66Met polymorphism and morphometric abnormalities in bipolar disorder.. Neuropsychopharmacology. 2009 Jul;34(8):1904-13.
95. Chepenik LG, Fredericks C, Papademetris X, Spencer L, Lacadie C, Wang F, et al. Effects of the brain-derived neurotrophic growth factor val66met variation on hippocampus morphology in bipolar disorder.. Neuropsychopharmacology. 2009 Mar;34(4):944-51.
96. Takahashi T, Suzuki M, Tsunoda M, Kawamura Y, Takahashi N, Tsuneki H, et al. Association between the brain-derived neurotrophic factor Val66Met polymorphism and brain morphology in a Japanese sample of schizophrenia and healthy comparisons.. Neurosci. Lett. 2008 Apr 11;435(1):34-9.
97. Koolschijn PCMP, Van Haren NEM, Bakker SC, Hoogendoorn MLC, Hulshoff Pol HE, Kahn RS. Effects of brain-derived neurotrophic factor Val66Met polymorphism on hippocampal volume change in schizophrenia. Hippocampus. 2010 Sep;20(9):1010-7.
98. Smith GN, Thornton AE, Lang DJ, Macewan GW, Ehmann TS, Kopala LC, et al. Hippocampal volume and the brain-derived neurotrophic factor Val66Met polymorphism in first episode psychosis.. Schizophr. Res. 2012 Feb;2(3-253):9-.
99. Carlino D, Leone E, Di Cola F, Baj G, Marin R, Dinelli G, et al. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia.. J Psychiatr Res. 2011 Feb;45(2):273-9.
100. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C, Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 2009 Sep;11(6):663-71.
101. Brietzke E, Mansur RB, Soczynska J, Powell AM, McIntyre RS. A theoretical framework informing research about the role of stress in the pathophysiology of bipolar disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2012 Oct 1;39(1):1-8.
102. Jones SR, Fernyhough C. A new look at the neural diathesis--stress model of schizophrenia: the primacy of social-evaluative and uncontrollable situations. Schizophr Bull. 2007.Sep;33(5):1171-7.
103. Fuchikami M, Morinobu S, Kurata A, Yamamoto S, Yamawaki S. Single immobilization stress differentially alters the expression profile of transcripts of the brain-derived neurotrophic factor (BDNF) gene and histone acetylation at its promoters in the rat hippocampus. Int. J. Neuropsychopharmacol. 2009 Feb;12(1):73-82.
104. Fumagalli F, Bedogni F, Perez J, Racagni G, Riva MA. Corticostriatal brain-derived neurotrophic factor dysregulation in adult rats following prenatal stress. Eur. J. Neurosci. 2004 Sep;20(5):1348-54.
105. Yulug B, Ozan E, Gönül AS, Kilic E. Brain-derived neurotrophic factor, stress and depression: a minireview. Brain Res. Bull. 2009 Mar 30;78(6):267-9.
106. Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat. Neurosci. 2006 Apr;9(4):519-25.
107. Sierksma ASR, Vanmierlo T, De Vry J, Raijmakers MEA, Steinbusch HWM, Van den Hove DLA, et al. Effects of prenatal stress exposure on soluble Aß and brain-derived neurotrophic factor signaling in male and female APPswe/PS1dE9 mice.. Neurochem. Int. 2012 Oct;61(5):697-701.
108. Neeley EW, Berger R, Koenig JI, Leonard S. Prenatal stress differentially alters brain-derived neurotrophic factor expression and signaling across rat strains. Neuroscience. 2011 Jul 28;187:24-35.
109. Belvederi Murri M, Pariante CM, Dazzan P, Hepgul N, Papadopoulos AS, Zunszain P, et al. Hypothalamic-pituitary-adrenal axis and clinical symptoms in first-episode psychosis.. Psychoneuroendocrinology. 2012 May;37(5):629-44.
110. Van der Werf-Eldering MJ, Riemersma-van der Lek RF, Burger H, Holthausen EAE, Aleman A, Nolen WA. Can variation in hypothalamic-pituitary-adrenal (HPA)-axis activity explain the relationship between depression and cognition in bipolar patients? PLoS ONE. 2012;7(5-e37119):.
111. Mondelli V, Dazzan P, Hepgul N, Di Forti M, Aas M, D'Albenzio A, et al. Abnormal cortisol levels during the day and cortisol awakening response in first-episode psychosis: the role of stress and of antipsychotic treatment.. Schizophr. Res. 2010 Feb;2(3-234):42-.
112. Valiengo LL, Soeiro-de-Souza MG, Marques AH, Moreno DH, Juruena MF, Andreazza AC, et al. Plasma cortisol in first episode drug-naive mania: differential levels in euphoric versus irritable mood.. J Affect Disord. 2012 Apr;138(1-2): 149-52.
113. Winkel R van, Stefanis NC, Myin-Germeys I. Psychosocial Stress and Psychosis. A Review of the Neurobiological Mechanisms and the Evidence for Gene-Stress Interaction. Schizophr Bull. 2008 Nov 1;34(6):1095-105.
114. Daban C, Vieta E, Mackin P, Young AH. Hypothalamic-pituitary-adrenal axis and bipolar disorder. Psychiatr. Clin. North Am. 2005 Jun;28(2):469-80.
115. Kumamaru E, Numakawa T, Adachi N, Yagasaki Y, Izumi A, Niyaz M, et al. Glucocorticoid prevents brain-derived neurotrophic factor-mediated maturation of synaptic function in developing hippocampal neurons through reduction in the activity of mitogen-activated protein kinase.. Mol. Endocrinol. 2008 Mar;22(3):546-58.
116. Aydemir O, Deveci A, Taneli F. The effect of chronic antidepressant treatment on serum brain-derived neurotrophic factor levels in depressed patients: a preliminary study. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2005 Feb;29(2):261-5.
117. Matrisciano F, Bonaccorso S, Ricciardi A, Scaccianoce S, Panaccione I, Wang L, et al. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.. J Psychiatr Res. 2009 Jan;43(3):247-54.
118. Lee H-Y, Kim Y-K. Plasma brain-derived neurotrophic factor as a peripheral marker for the action mechanism of antidepressants.. Neuropsychobiology. 2008;57(4): 194-9.
119. Schmidt HD, Duman RS. Peripheral BDNF produces antidepressant-like effects in cellular and behavioral models. Neuropsychopharmacology. 2010 Nov;35(12):2378-91.
120. Kaufman J, Yang B-Z, Douglas-Palumberi H, Grasso D, Lipschitz D, Houshyar S, et al. Brain-derived neurotrophic factor-5-HTTLPR gene interactions and environmental modifiers of depression in children.. Biol. Psychiatry. 2006 Apr 15;59(8):673-80.
121. Wichers M, Kenis G, Jacobs N, Mengelers R, Derom C, Vlietinck R, et al. The BDNF Val(66)Met x 5-HTTLPR x child adversity interaction and depressive symptoms: An attempt at replication.. Am. J. Med. Genet. B Neuropsychiatr. Genet. 2008 Jan 5;147B(1):120-3.
122. Kim J-M, Stewart R, Kim S-W, Yang S-J, Shin I-S, Kim Y-H, et al. Interactions between life stressors and susceptibility genes (5-HTTLPR and BDNF) on depression in Korean elders.. Biol. Psychiatry. 2007 Sep 1;62(5):423-8.
123. Grabe HJ, Schwahn C, Mahler J, Appel K, Schulz A, Spitzer C, et al. Genetic epistasis between the brain-derived neurotrophic factor Val66Met polymorphism and the 5-HTT promoter polymorphism moderates the susceptibility to depressive disorders after childhood abuse. Prog. Neuropsychopharmacol.. Biol. Psychiatry. 2012 Mar 30;36(2):264-70.
124. Weickert CS, Hyde TM, Lipska BK, Herman MM, Weinberger DR, Kleinman JE. Reduced brain-derived neurotrophic factor in prefrontal cortex of patients with schizophrenia. Molecular Psychiatry. 2003;8(6-592):610-.
125. Hashimoto T, Bergen SE, Nguyen QL, Xu B, Monteggia LM, Pierri JN, et al. Relationship of Brain-Derived Neurotrophic Factor and Its Receptor TrkB to Altered Inhibitory Prefrontal Circuitry in Schizophrenia.. J. Neurosci. 2005 Jan 12;25(2):372-83.
126. Pillai A. Decreased expression of Sprouty2 in the dorsolateral prefrontal cortex in schizophrenia and bipolar disorder: a correlation with BDNF expression. PLoS ONE. 2008;3(3-e1784):.
127. Issa G, Wilson C, Terry Jr. AV, Pillai A. An inverse relationship between cortisol and BDNF levels in schizophrenia: Data from human postmortem and animal studies. Neurobiology of Disease. 2010 Sep;39(3):327-33.
128. Takahashi M, Shirakawa O, Toyooka K, Kitamura N, Hashimoto T, Maeda K, et al. Abnormal expression of brain-derived neurotrophic factor and its receptor in the corticolimbic system of schizophrenic patients.. Mol. Psychiatry. 2000 May;5(3):293-300.
129. Dunham JS, Deakin JFW, Miyajima F, Payton A, Toro CT. Expression of hippocampal brain-derived neurotrophic factor and its receptors in Stanley consortium brains. Journal of Psychiatric Research. 2009 Sep;43(14):1175-84.
130. Thompson Ray M, Weickert CS, Wyatt E, Webster MJ. Decreased BDNF, trkB-TK+ and GAD67 mRNA expression in the hippocampus of individuals with schizophrenia and mood disorders. J Psychiatry Neurosci. 2011 May;36(3):195-203.
131. Buckley PF, Pillai A, Evans D, Stirewalt E, Mahadik S. Brain derived neurotropic factor in first-episode psychosis. Schizophr. Res. 2007 Mar;1(3-1):5-.
132. Pillai A, Kale A, Joshi S, Naphade N, Raju MSVK, Nasrallah H, et al. Decreased BDNF levels in CSF of drug-naive first-episode psychotic subjects: correlation with plasma BDNF and psychopathology.. Int. J. Neuropsychopharmacol. 2010 May;13(4):535-9.
133. Rizos EN, Rontos I, Laskos E, Arsenis G, Michalopoulou PG, Vasilopoulos D, et al. Investigation of serum BDNF levels in drug-naive patients with schizophrenia.. Progress in Neuro-Psychopharmacology and Biological Psychiatry. 2008 Jul 1;32(5):1308-11.
134. Jindal RD, Pillai AK, Mahadik SP, Eklund K, Montrose DM, Keshavan MS. Decreased BDNF in patients with antipsychotic naive first episode schizophrenia. Schizophr. Res. 2010 Jun;1(3-47):51-.
135. Chen DC, Wang J, Wang B, Yang SC, Zhang CX, Zheng YL, et al. Decreased levels of serum brain-derived neurotrophic factor in drug-nai've first-episode schizophrenia: relationship to clinical phenotypes.. Psychopharmacology. (Berl.). 2009 Dec;207(3):375-80.
136. Yoshimura R, Hori H, Sugita A, Ueda N, Kakihara S, Umene W, et al. Treatment with risperidone for 4 weeks increased plasma 3-methoxy-4-hydroxypnenylglycol (MHPG) levels, but did not alter plasma brain-derived neurotrophic factor (BDNF) levels in schizophrenic patients. Prog. Neuropsychopharmacol.. Biol. Psychiatry. 2007 Jun 30;31(5):1072-7.
137. Tan YL, Zhou DF, Cao LY, Zou YZ, Zhang XY. Decreased BDNF in serum of patients with chronic schizophrenia on long-term treatment with antipsychotics. Neurosci. Lett. 2005 Jul 1;382(1-2):27-32.
138. Grillo RW, Ottoni GL, Leke R, Souza DO, Portela LV, Lara DR. Reduced serum BDNF levels in schizophrenic patients on clozapine or typical antipsychotics. J Psychiatr Res. 2007 Feb;1(2-31):5-.
139. Pirildar S, Gönül AS, Taneli F, Akdeniz F. Low serum levels of brain-derived neurotrophic factor in patients with schizophrenia do not elevate after antipsychotic treatment. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2004 Jul;28(4):709-13.
140. Toyooka K, Asama K, Watanabe Y, Muratake T, Takahashi M, Someya T, et al. Decreased levels of brain-derived neurotrophic factor in serum of chronic schizophrenic patients.. Psychiatry Res. 2002 Jul 31;110(3):249-57.
141. Xiu MH, Hui L, Dang YF, Hou TD, Zhang CX, Zheng YL, et al. Decreased serum BDNF levels in chronic institutionalized schizophrenia on long-term treatment with typical and atypical antipsychotics.. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2009 Nov 13;33(8): 1508-12.
142. Vinogradov S, Fisher M, Holland C, Shelly W, Wolkowitz O, Mellon SH. Is serum brain-derived neurotrophic factor a biomarker for cognitive enhancement in schizophrenia? Biol. Psychiatry. 2009 Sep 15;66(6):549-53.
143. Reis HJ, Nicolato R, Barbosa IG, Prado PHT do, Romano-Silva MA, Teixeira AL. Increased serum levels of brain-derived neurotrophic factor in chronic institutionalized patients with schizophrenia. Neuroscience Letters. 2008 Jul 11;439(2):157-9.
144. Mackin P, Gallagher P, Watson S, Young AH, Ferrier IN. Changes in brain-derived neurotrophic factor following treatment with mifepristone in bipolar disorder and schizophrenia. Aust N Z J Psychiatry. 2007 Apr;41(4):321-6.
145. Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry. 2008 Sep 15;64(6):527-32.
146. Malhi GS, Tanious M, Das P, Coulston CM, Berk M. Potential Mechanisms of Action of Lithium in Bipolar Disorder : Current Understanding. CNSDrugs. 2013 Feb 1;
147. Machado-Vieira R, Dietrich MO, Leke R, Cereser VH, Zanatto V, Kapczinski F, et al. Decreased plasma brain derived neurotrophic factor levels in unmedicated bipolar patients during manic episode.. Biol. Psychiatry. 2007 Jan 15;61(2):142-4.
148. Tramontina JF, Andreazza AC, Kauer-Sant'anna M, Stertz L, Goi J, Chiarani F, et al. Brain-derived neurotrophic factor serum levels before and after treatment for acute mania.. Neurosci. Lett. 2009 Mar 13;452(2):111-3.
149. Cunha ABM, Frey BN, Andreazza AC, Goi JD, Rosa AR, Gonçalves CA, et al. Serum brain-derived neurotrophic factor is decreased in bipolar disorder during depressive and manic episodes.. Neurosci. Lett. 2006 May 8;398(3):215-9.
150. Monteleone P, Serritella C, Martiadis V, Maj M. Decreased levels of serum brain-derived neurotrophic factor in both depressed and euthymic patients with unipolar depression and in euthymic patients with bipolar
151. De Oliveira GS, Ceresér KM, Fernandes BS, Kauer-Sant'Anna M, Fries GR, Stertz L, et al. Decreased brain-derived neurotrophic factor in medicated and drug-free bipolar patients.. J Psychiatr Res. 2009 Sep;43(14):1171-4.
152. Gama CS, Andreazza AC, Kunz M, Berk M, Belmonte-de-Abreu PS, Kapczinski F. Serum levels of brain-derived neurotrophic factor in patients with schizophrenia and bipolar disorder. Neurosci. Lett. 2007 Jun 8;420(1):45-8.
153. Green MF. Cognitive impairment and functional outcome in schizophrenia and bipolar disorder. J Clin Psychiatry. 2006;67 Suppl 9:3-8; discussion 36-42.
154. Goldberg JF, Chengappa KNR. Identifying and treating cognitive impairment in bipolar disorder.. Bipolar Disord. 2009 Jun;11 Suppl 2:123-37.
155. Hill SK, Reilly JL, Harris MSH, Rosen C, Marvin RW, Deleon O, et al. A comparison of neuropsychological dysfunction in first-episode psychosis patients with unipolar depression, bipolar disorder, and schizophrenia.. Schizophr. Res. 2009 Sep;2(3-167):75-.
156. Jabben N, Arts B, Van Os J, Krabbendam L. Neurocognitive functioning as intermediary phenotype and predictor of psychosocial functioning across the psychosis continuum: studies in schizophrenia and bipolar disorder. J Clin Psychiatry. 2010 Jun;71(6):764-74.
157. Krabbendam L, Arts B, Van Os J, Aleman A. Cognitive functioning in patients with schizophrenia and bipolar disorder: a quantitative review. Schizophr. Res. 2005 Dec 15;80(2-3):137-49.
158. Simonsen C, Sundet K, Vaskinn A, Birkenaes AB, Engh JA, Faerden A, et al. Neurocognitive dysfunction in bipolar and schizophrenia spectrum disorders depends on history of psychosis rather than diagnostic group.. Schizophr Bull. 2011 Jan;37(1):73-83.
159. Tan YL, Zhou DF, Cao LY, Zou YZ, Wu GY, Zhang XY. Effect of the BDNF Val66Met genotype on episodic memory in schizophrenia. Schizophrenia Research. 2005 Sep 15;77(2-3):355-6.
160. Ho B-C, Milev P, O'Leary DS, Librant A, Andreasen NC, Wassink TH. Cognitive and magnetic resonance imaging brain morphometric correlates of brain-derived neurotrophic factor Val66Met gene polymorphism in patients with schizophrenia and healthy volunteers. Arch. Gen. Psychiatry. 2006 Jul;63(7):731-40.
161. Carlino D, Leone E, Di Cola F, Baj G, Marin R, Dinelli G, et al. Low serum truncated-BDNF isoform correlates with higher cognitive impairment in schizophrenia.. J Psychiatr Res. 2011 Feb;45(2):273-9.
162. Rybakowski JK, Borkowska A, Skibinska M, Szczepankiewicz A, Kapelski P, Leszczynska-Rodziewicz A, et al. Prefrontal cognition in schizophrenia and bipolar illness in relation to Val66Met polymorphism of the brain-derived neurotrophic factor gene.. Psychiatry Clin. Neurosci. 2006 Feb;60(1):70-6.
163. Dias VV, Brissos S, Frey BN, Andreazza AC, Cardoso C, Kapczinski F. Cognitive function and serum levels of brain-derived neurotrophic factor in patients with bipolar disorder. Bipolar Disord. 2009 Sep;11(6):663-71.
164. Tramontina JF, Yates D, Magalhaes PV da S, Trentini C, Sant'anna MK, Fries GR, et al. Brain-derived neurotrophic factor gene val66met polymorphism and executive functioning in patients with bipolar disorder.. Rev Bras Psiquiatr. 2009 Jun;31(2):136-40.
165. Chou Y-H, Wang S-J, Lirng J-F, Lin C-L, Yang K-C, Chen C-K, et al. Impaired cognition in bipolar I disorder: the roles of the serotonin transporter and brain-derived neurotrophic factor.. J Affect Disord. 2012 Dec 20;143(1-3): 131-7.
166. Mandelman SD, Grigorenko EL. BDNF Val66Met and cognition: all, none, or some? A meta-analysis of the genetic association. Genes Brain Behav. 2012 Mar;11(2):127-36.
167. Rose EJ, Donohoe G. Brain vs Behavior: An Effect Size Comparison of Neuroimaging and Cognitive Studies of Genetic Risk for Schizophrenia. Schizophr Bull. 2012 Apr 12;
168. Fernandes BS, Gama CS, Kauer-Sant'Anna M, Lobato MI, Belmonte-de-Abreu P, Kapczinski F. Serum brain-derived neurotrophic factor in bipolar and unipolar depression: a potential adjunctive tool for differential diagnosis. J Psychiatr Res. 2009 Oct;43(15):1200-4.
169. Costafreda SG, Fu CHY, Picchioni M, Toulopoulou T, McDonald C, Kravariti E, et al. Pattern of neural responses to verbal fluency shows diagnostic specificity for schizophrenia and bipolar disorder. BMC Psychiatry. 2011;11:18.